The use of warfarin as thromboprophylaxis for lower limb arthroplasty

Annals of the Royal College of Surgeons of England

Volumn 90, Issue 6, 2008, Pages 500-503

  Dunbar, Mark R ^a   Upadhyay, Piyush K ^a   Karthikeyan, Shanmugan ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Arthroplasty; Medical audit; Warfarin

Indexed keywords

WARFARIN;

ARTHROPLASTY; ARTICLE; CLINICAL ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EVENING DOSAGE; HEALTH CARE COST; HOSPITAL BED UTILIZATION; HOSPITAL DISCHARGE; HOSPITAL UTILIZATION; HUMAN; LENGTH OF STAY; LOWER LIMB ARTHROPLASTY; MEDICAL AUDIT; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CLINICAL PROTOCOLS; COSTS AND COST ANALYSIS; HUMANS; LENGTH OF STAY; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM; WARFARIN;

EID: 52649178378     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588408X300957     Document Type: Article

References (9)

1. Brenkel IJ, Cook RE. Thromboprophylaxis in patients undergoing total hip replacement. Hosp Med 2003; 64: 281-7.
2. Amstutz HC, Friscia DA, Dorey F, Carney BT. Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. J Bone Joint Surg Am 1989; 71: 321-6.
3. Lowe GD, Greer IA, Cooke TG. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ 1992; 305: 567-74.
4. Murray DW, Britton AR, Bulstrode CJ. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br 1996; 78: 863-70.
5. Tria Jr AJ, Coon TM. Minimal incision total knee arthroplasty: early experience. Clin Orthop 2003; 416: 185-90.
6. Hallinen T, Martikainen JA, Soini EJ, Suominen L, Aronkyto T. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Curr Med Res Opin 2006; 22: 683-92.
7. Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005; 39: 446-51.
8. Anderson DR, O'Brien BJ. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. Pharmacoeconomics 1997; 12: 17-29.
9. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl): 338S-400S.